Clinical trial

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

NCT03964337

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-03-17

PhasePHASE2

Study timeline

Study start (actual)2020-03-17Date precision: day

Registry last updated2022-06-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Prostate Cancer Adenocarcinomaunresolved

Non-Metastaticunresolved

Interventions

CabozantinibDRUG · verified · RxNorm: cabozantinib

Radical ProstatectomyPROCEDURE

Sponsors & collaborators

Duke Universitylead sponsor

Exelixiscollaborator

Mapped research locations

DurhamNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03964337 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.